Cointime

Osivax

company

About

Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.

  • 11 - 50

Highlights

Total Funding Amount
€30.10M
Funding Rounds
2
Investors
1

Details

Last Funding Type
Grant
Last Funding Money Raised
€15.10M
Industries
Biotechnology,Clinical Trials,Health Care
Founded date
Jan 1, 2017
Number Of Employee
11 - 50
Operating Status
Active

​Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medical practitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€30.10M
Osivax has raised a total of €30.10M in funding over 2 rounds. Their latest funding was raised on Jul 8, 2020 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 8, 2020 Grant €15.10M 1 — — Detail
Jul 8, 2020 Series B €15M 1 European Innovation Council — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Osivax is funded by 1 investors. European Innovation Council are the most recent investors.
Investor Name Lead Investor Funding Round
European Innovation Council — Grant
Cointime
เนื้อหา
บริษัท